586 related articles for article (PubMed ID: 8707404)
1. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort.
Persson I; Yuen J; Bergkvist L; Schairer C
Int J Cancer; 1996 Jul; 67(3):327-32. PubMed ID: 8707404
[TBL] [Abstract][Full Text] [Related]
2. Menopausal hormone therapy and cancer risk: An overestimated risk?
Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
[TBL] [Abstract][Full Text] [Related]
3. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
5. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
6. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.
Anderson GL; Judd HL; Kaunitz AM; Barad DH; Beresford SA; Pettinger M; Liu J; McNeeley SG; Lopez AM;
JAMA; 2003 Oct; 290(13):1739-48. PubMed ID: 14519708
[TBL] [Abstract][Full Text] [Related]
7. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
Stanford JL; Weiss NS; Voigt LF; Daling JR; Habel LA; Rossing MA
JAMA; 1995 Jul; 274(2):137-42. PubMed ID: 7596001
[TBL] [Abstract][Full Text] [Related]
8. Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for 'healthy drug-user' effect.
Yuen J; Persson I; Bergkvist L; Hoover R; Schairer C; Adami HO
Cancer Causes Control; 1993 Jul; 4(4):369-74. PubMed ID: 8394149
[TBL] [Abstract][Full Text] [Related]
9. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement.
Persson I; Weiderpass E; Bergkvist L; Bergström R; Schairer C
Cancer Causes Control; 1999 Aug; 10(4):253-60. PubMed ID: 10482483
[TBL] [Abstract][Full Text] [Related]
10. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
van Leeuwen FE
Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
[TBL] [Abstract][Full Text] [Related]
11. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
[TBL] [Abstract][Full Text] [Related]
12. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy.
Nachtigall MJ; Smilen SW; Nachtigall RD; Nachtigall RH; Nachtigall LE
Obstet Gynecol; 1992 Nov; 80(5):827-30. PubMed ID: 1328978
[TBL] [Abstract][Full Text] [Related]
13. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
[TBL] [Abstract][Full Text] [Related]
14. The risk of breast cancer after estrogen and estrogen-progestin replacement.
Bergkvist L; Adami HO; Persson I; Hoover R; Schairer C
N Engl J Med; 1989 Aug; 321(5):293-7. PubMed ID: 2546079
[TBL] [Abstract][Full Text] [Related]
15. Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening.
Persson I; Thurfjell E; Bergstrom R; Holmberg L
Int J Cancer; 1997 Sep; 72(5):758-61. PubMed ID: 9311590
[TBL] [Abstract][Full Text] [Related]
16. Risk of endometrial cancer following estrogen replacement with and without progestins.
Weiderpass E; Adami HO; Baron JA; Magnusson C; Bergström R; Lindgren A; Correia N; Persson I
J Natl Cancer Inst; 1999 Jul; 91(13):1131-7. PubMed ID: 10393721
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-term estrogen replacement therapy. II. Neoplasia.
Hammond CB; Jelovsek FR; Lee KL; Creasman WT; Parker RT
Am J Obstet Gynecol; 1979 Mar; 133(5):537-47. PubMed ID: 220875
[TBL] [Abstract][Full Text] [Related]
18. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort.
Lacey JV; Leitzmann MF; Chang SC; Mouw T; Hollenbeck AR; Schatzkin A; Brinton LA
Cancer; 2007 Apr; 109(7):1303-11. PubMed ID: 17315161
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden.
Falkeborn M; Persson I; Terént A; Adami HO; Lithell H; Bergström R
Arch Intern Med; 1993 May; 153(10):1201-9. PubMed ID: 8388207
[TBL] [Abstract][Full Text] [Related]
20. Cancer issues.
Marsden J; Sturdee D
Best Pract Res Clin Obstet Gynaecol; 2009 Feb; 23(1):87-107. PubMed ID: 19036643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
